Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

504 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b/c Trial.
Espinosa-Pereiro J, Ghimire S, Sturkenboom MGG, Alffenaar JC, Tavares M, Aguirre S, Battaglia A, Molinas G, Tórtola T, Akkerman OW, Sanchez-Montalva A, Magis-Escurra C. Espinosa-Pereiro J, et al. Among authors: ghimire s. Pharmaceutics. 2022 Dec 20;15(1):9. doi: 10.3390/pharmaceutics15010009. Pharmaceutics. 2022. PMID: 36678638 Free PMC article.
Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis.
Ghimire S, Maharjan B, Jongedijk EM, Kosterink JGW, Ghimire GR, Touw DJ, van der Werf TS, Shrestha B, Alffenaar JC. Ghimire S, et al. Among authors: ghimire gr. Antimicrob Agents Chemother. 2019 Apr 25;63(5):e02379-18. doi: 10.1128/AAC.02379-18. Print 2019 May. Antimicrob Agents Chemother. 2019. PMID: 30782999 Free PMC article.
Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs.
Kuhlin J, Sturkenboom MGG, Ghimire S, Margineanu I, van den Elsen SHJ, Simbar N, Akkerman OW, Jongedijk EM, Koster RA, Bruchfeld J, Touw DJ, Alffenaar JC. Kuhlin J, et al. Among authors: ghimire s. Clin Mass Spectrom. 2018 Oct 19;14 Pt A:34-45. doi: 10.1016/j.clinms.2018.10.002. eCollection 2019 Sep. Clin Mass Spectrom. 2018. PMID: 34934812 Free PMC article. Review.
Corrigendum to "Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs" [Clin. Mass Spectrom. 14(Part A) (2019) 34-45].
Kuhlin J, Sturkenboom MGG, Ghimire S, Margineanu I, van den Elsen SHJ, Simbar N, Akkerman OW, Jongedijk EM, Koster RA, Bruchfeld J, Touw DJ, Alffenaar JC. Kuhlin J, et al. Among authors: ghimire s. J Mass Spectrom Adv Clin Lab. 2022 Aug 13;25:72. doi: 10.1016/j.jmsacl.2022.08.001. eCollection 2022 Aug. J Mass Spectrom Adv Clin Lab. 2022. PMID: 36035622 Free PMC article.
Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid.
van den Elsen SHJ, Akkerman OW, Wessels M, Jongedijk EM, Ghimire S, van der Werf TS, Bolhuis MS, Touw DJ, Alffenaar JC. van den Elsen SHJ, et al. Among authors: ghimire s. Eur Respir J. 2020 Oct 22;56(4):2000803. doi: 10.1183/13993003.00803-2020. Print 2020 Oct. Eur Respir J. 2020. PMID: 32398308 Free article. No abstract available.
504 results